Pre-treatment with curcumin enhances plasma concentrations of losartan and its metabolite EXP3174 in rats

Biological and Pharmaceutical Bulletin

Volumn 35, Issue 2, 2012, Pages 145-150

  Liu, An Chang ^a,b   Zhao, Li Xia ^a,b   Xing, Jie ^a   Liu, Tian ^a   Du, Fu Ying ^a   Lou, Hong Xiang ^a  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

Curcumin; Interaction; Losartan

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; CARBOXYMETHYLCELLULOSE; CURCUMIN; IRBESARTAN; LOSARTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG POTENTIATION; DRUG STRUCTURE; FEMALE; HYPERTENSION; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; RAT; REPEATED DRUG DOSE; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANIMALS; ANTIOXIDANTS; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CURCUMIN; FEMALE; IMIDAZOLES; LOSARTAN; MALE; RATS; RATS, WISTAR; TANDEM MASS SPECTROMETRY; TETRAZOLES;

EID: 84863399226     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.35.145     Document Type: Article

References (31)

1. Kamper M, Tsimpoukidi O, Chatzigeorgiou A, Lymberi M, Kamper EF. The antioxidant effect of angiotensin II receptor blocker, losartan, in streptozotocin-induced diabetic rats. Transl. Res., 156, 26-36 (2010).
2. Argani H, Ghorbanihaghjo A, Aghaeishahsavari M, Noroozianavval M, Rashtchizadeh N, Veisi P, Safa J, Abediazar S. Effects of losartan and enalapril on high-sensitivity C-reactive protein and total antioxidant in renal transplant recipients with Renin-Angiotensin system polymorphisms. Transplant. Proc., 40, 16-21 (2008).
3. Yao EH, Fukuda N, Matsumoto T, Kobayashi N, Katakawa M, Yamamoto C, Tsunemi A, Suzuki R, Ueno T, Matsumoto K. Losartan improves the impaired function of endothelial progenitor cells in hypertension via an antioxidant effect. Hypertens. Res., 30, 1119-1128 (2007).
4. Liptáková A, Ulicná O, Duracková Z, Bozek P, Vancová O. Effect of losartan on antioxidant status in rats with diabetes mellitus. Ceska Slov. Farm., 50, 193-196 (2001).
5. García G, Rodríguez-Puyol M, Alajarín R, Serrano I, Sánchez-Alonso P, Griera M, Vaquero JJ, Rodríguez-Puyol D, Alvarez-Builla J, Díez-Marqués ML. Losartan-antioxidant hybrids: novel molecules for the prevention of hypertension-induced cardiovascular damage. J. Med. Chem., 52, 7220-7227 (2009).
6. Chan MM. Inhibition of tumor necrosis factor by curcumin, a phytochemical. Biochem. Pharmacol., 49, 1551-1556 (1995).
7. Zhong F, Chen H, Han L, Jin Y, Wang W. Curcumin attenuates lipopolysaccharide-induced renal inflammation. Biol. Pharm. Bull., 34, 226-232 (2011).
8. Brouet I, Ohshima H. Curcumin, an anti-tumour promoter and anti-inflammatory agent, inhibits induction of nitric oxide synthase in activated macrophages. Biochem. Biophys. Res. Commun., 206, 533-540 (1995).
9. Guangwei X, Rongzhu L, Wenrong X, Suhua W, Xiaowu Z, Shizhong W, Ye Z, Aschner M, Kulkarni SK, Bishnoi M. Curcumin pretreatment protects against acute acrylonitrile-induced oxidative damage in rats. Toxicology, 267, 140-146 (2010).
10. Surveswaran S, Cai Y, Corke H, Sun M. Systematic evaluation of natural phenolic antioxidants from 133 Indian medicinal plants. Food Chem., 102, 938-953 (2007).
11. Sharma RA, Euden SA, Platton SL, Cooke DN, Shafayat A, Hewitt HR, Marczylo TH, Morgan B, Hemingway D, Plummer SM, Pirmohamed M, Gescher AJ, Steward WP. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin. Cancer Res., 10, 6847-6854 (2004).
12. Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, Ko JY, Lin JT, Lin BR, Ming-Shiang W, Yu HS, Jee SH, Chen GS, Chen TM, Chen CA, Lai MK, Pu YS, Pan MH, Wang YJ, Tsai CC, Hsieh CY. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res., 21(4B), 2895-2900 (2001).
13. Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL, Ng CS, Badmaev V, Kurzrock R. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin. Cancer Res., 14, 4491-4499 (2008).
14. Zhang W, Tan TM, Lim LY. Impact of curcumin-induced changes in P-glycoprotein and CYP3A expression on the pharmacokinetics of peroral celiprolol and midazolam in rats. Drug Metab. Dispos., 35, 110-115 (2007).
15. Aguilar F, Dusemund B, Galtier P, Gilbert J, Gott DM, Grilli S, Gürtler R, König J, Lambré C, Larsen J-C, Leblanc J-C, Mortensen A, Parent-Massin D, Pratt I, Rietjens IMCM, Stankovic I, Tobback P, Verguieva T, Woutersen RA. Re-evaluation of curcumin (E 100) as a food additive. EFSA Journal, 8, 1679 (2010).
16. Yao QH, Wang DQ, Cui CC, Yuan ZY, Chen SB, Yao XW, Wang JK, Lian JF. Curcumin ameliorates left ventricular function in rabbits with pressure overload: inhibition of the remodeling of the left ventricular collagen network associated with suppression of myocardial tumor necrosis factor-alpha and matrix metalloproteinase-2 expression. Biol. Pharm. Bull., 27, 198-202 (2004).
17. Ramaswami G, Chai H, Yao Q, Lin PH, Lumsden AB, Chen C. Curcumin blocks homocysteine-induced endothelial dysfunction in porcine coronary arteries. J. Vasc. Surg., 40, 1216-1222 (2004).
18. Faulx MD, Francis GS. Adverse drug reactions in patients with cardiovascular disease. Curr. Probl. Cardiol., 33, 703-768 (2008).
19. Song JC, White CM. Pharmacologic, pharmacokinetic, and therapeutic differences among angiotensin II receptor antagonists. Pharmacotherapy, 20, 130-139 (2000).
20. McIntyre M, Caffe SE, Michalak RA, Reid JL. Losartan, an orally active angiotensin (AT1) receptor antagonist: a review of its efficacy and safety in essential hypertension. Pharmacol. Ther., 74, 181-194 (1997).
21. Suzuki J, Ohta H, Hanada K, Kawai N, Ikeda T, Nakao M, Ikemoto F, Nishikibe M. Acute effects of E-3174, a human active metabolite of losartan, on the cardiovascular system in tachycardia-induced canine heart failure. Hypertens. Res., 24, 65-74 (2001).
22. Yan YD, Kim DH, Sung JH, Yong CS, Choi HG. Enhanced oral bioavailability of docetaxel in rats by four consecutive days of pretreatment with curcumin. Int. J. Pharm., 399, 116-120 (2010).
23. Kobayashi M, Takagi M, Fukumoto K, Kato R, Tanaka K, Ueno K. The effect of bucolome, a CYP2C9 inhibitor, on the pharmacokinetics of losartan. Drug Metab. Pharmacokinet., 23, 115-119 (2008).
24. Díez J. Review of the molecular pharmacology of Losartan and its possible relevance to stroke prevention in patients with hypertension. Clin. Ther., 28, 832-848 (2006).
25. Stearns RA, Chakravarty PK, Chen R, Chiu SH. Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members. Drug Metab. Dispos., 23, 207-215 (1995).
26. Hou XL, Takahashi K, Tanaka K, Tougou K, Qiu F, Komatsu K, Takahashi K, Azuma J. Curcuma drugs and curcumin regulate the expression and function of P-gp in Caco-2 cells in completely opposite ways. Int. J. Pharm., 358, 224-229 (2008).
27. Pavithra BH, Prakash N, Jayakumar K. Modification of pharmacokinetics of norfloxacin following oral administration of curcumin in rabbits. J. Vet. Sci., 10, 293-297 (2009).
28. Basu NK, Kole L, Kubota S, Owens IS. Human UDP-glucuronosyltransferases show atypical metabolism of mycophenolic acid and inhibition by curcumin. Drug Metab. Dispos., 32, 768-773 (2004).
29. Krieter PA, Colletti AE, Miller RR, Stearns RA. Absorption and glucuronidation of the angiotensin II receptor antagonist losartan by the rat intestine. J. Pharmacol. Exp. Ther., 273, 816-822 (1995).
30. Klein TE, Chang JT, Cho MK, Easton KL, Fergerson R, Hewett M, Lin Z, Liu Y, Liu S, Oliver DE, Rubin DL, Shafa F, Stuart JM, Altman RB. Integrating genotype and phenotype information: an overview of the PharmGKB project. Pharmacogenetics Research Network and Knowledge Base. Pharmacogenomics J., 1, 167-170 (2001).
31. Iwasa T, Takano T, Hara K, Kamei T. Method for the simultaneous determination of losartan and its major metabolite, EXP-3174, in human plasma by liquid chromatography-electrospray ionization tandem mass spectrometry. J. Chromatogr. B Biomed. Sci. Appl., 734, 325-330 (1999).